HUP0100388A3 - Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol - Google Patents
Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterolInfo
- Publication number
- HUP0100388A3 HUP0100388A3 HU0100388A HUP0100388A HUP0100388A3 HU P0100388 A3 HUP0100388 A3 HU P0100388A3 HU 0100388 A HU0100388 A HU 0100388A HU P0100388 A HUP0100388 A HU P0100388A HU P0100388 A3 HUP0100388 A3 HU P0100388A3
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- pharmaceutical compositions
- treating osteoporosis
- lowering cholesterol
- cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18892300P | 2000-01-26 | 2000-01-26 | |
US20532700P | 2000-04-21 | 2000-04-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0100388D0 HU0100388D0 (en) | 2001-03-28 |
HUP0100388A2 HUP0100388A2 (hu) | 2003-08-28 |
HUP0100388A3 true HUP0100388A3 (en) | 2006-02-28 |
Family
ID=26884589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0100388A HUP0100388A3 (en) | 2000-01-26 | 2001-01-25 | Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol |
Country Status (12)
Country | Link |
---|---|
US (2) | US6756401B2 (hu) |
EP (1) | EP1123717A3 (hu) |
JP (1) | JP2001206845A (hu) |
KR (1) | KR20010083135A (hu) |
AU (1) | AU780568B2 (hu) |
CA (1) | CA2332214A1 (hu) |
CO (1) | CO5251465A1 (hu) |
HU (1) | HUP0100388A3 (hu) |
IL (1) | IL140989A0 (hu) |
MY (1) | MY133564A (hu) |
NZ (1) | NZ523651A (hu) |
PE (1) | PE20011294A1 (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001271784A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
EP1296674A2 (en) * | 2000-07-06 | 2003-04-02 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
EP1643969A2 (en) * | 2003-07-11 | 2006-04-12 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
EP1718146A2 (en) * | 2004-02-13 | 2006-11-08 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
JP2008500368A (ja) * | 2004-05-27 | 2008-01-10 | ミジェニックス コーポレイション | 細胞保護のための2置換17−イミノエストロゲン化合物 |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するためのチエノピリジン |
EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US8501690B2 (en) * | 2010-04-30 | 2013-08-06 | John G. Stark | Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue |
PL2580210T3 (pl) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals, Inc. | Modulatory receptora estrogenowego i ich zastosowania |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
BR112018006121B1 (pt) | 2015-10-01 | 2024-01-23 | Olema Pharmaceuticals, Inc | COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS |
WO2017100715A1 (en) | 2015-12-09 | 2017-06-15 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3478294A4 (en) | 2016-07-01 | 2020-06-10 | G1 Therapeutics, Inc. | PYRIMIDINE-BASED ANTIPROLIFERATIVE ACTIVE SUBSTANCES |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
EA201991622A1 (ru) | 2017-01-06 | 2020-01-23 | Г1 Терапьютикс, Инк. | Комплексная терапия для лечения рака |
EA201992768A1 (ru) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (hu) * | 1974-06-07 | 1981-03-18 | ||
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
NO177005C (no) * | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
AU673660C (en) * | 1991-12-18 | 2002-07-25 | Astrazeneca Ab | New combination of formoterol and budesonide |
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
ZA979644B (en) | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
ATE311872T1 (de) | 1996-12-13 | 2005-12-15 | Zymogenetics Inc | Zusammensetzungen und verfahren zum stimulieren von knochenwachstum |
US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
WO1999045923A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Methods of inhibiting bone resorption |
-
2000
- 2000-12-28 CO CO00098264A patent/CO5251465A1/es not_active Application Discontinuation
-
2001
- 2001-01-18 IL IL14098901A patent/IL140989A0/xx unknown
- 2001-01-22 EP EP01300527A patent/EP1123717A3/en not_active Withdrawn
- 2001-01-22 KR KR1020010003519A patent/KR20010083135A/ko not_active Application Discontinuation
- 2001-01-22 MY MYPI20010286A patent/MY133564A/en unknown
- 2001-01-23 US US09/767,625 patent/US6756401B2/en not_active Expired - Fee Related
- 2001-01-24 PE PE2001000079A patent/PE20011294A1/es not_active Application Discontinuation
- 2001-01-24 JP JP2001015626A patent/JP2001206845A/ja active Pending
- 2001-01-24 CA CA002332214A patent/CA2332214A1/en not_active Abandoned
- 2001-01-25 HU HU0100388A patent/HUP0100388A3/hu unknown
- 2001-01-25 AU AU16675/01A patent/AU780568B2/en not_active Ceased
- 2001-01-25 NZ NZ523651A patent/NZ523651A/en unknown
-
2004
- 2004-05-06 US US10/840,577 patent/US20040259886A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL140989A0 (en) | 2002-02-10 |
US20030162807A1 (en) | 2003-08-28 |
AU780568B2 (en) | 2005-04-07 |
EP1123717A2 (en) | 2001-08-16 |
NZ523651A (en) | 2004-06-25 |
CO5251465A1 (es) | 2003-02-28 |
KR20010083135A (ko) | 2001-08-31 |
HUP0100388A2 (hu) | 2003-08-28 |
AU1667501A (en) | 2001-08-02 |
MY133564A (en) | 2007-11-30 |
CA2332214A1 (en) | 2001-07-26 |
US20040259886A1 (en) | 2004-12-23 |
PE20011294A1 (es) | 2001-12-21 |
EP1123717A3 (en) | 2003-10-15 |
HU0100388D0 (en) | 2001-03-28 |
JP2001206845A (ja) | 2001-07-31 |
US6756401B2 (en) | 2004-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0100388A3 (en) | Pharmaceutical compositions and methods for treating osteoporosis and lowering cholesterol | |
EP1446114A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS | |
AUPQ127399A0 (en) | Compositions and methods for treating or preventing osteoporosis | |
NZ514350A (en) | Compositions and methods for effecting the levels of cholesterol | |
EP1212065A4 (en) | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL | |
HU0103078D0 (en) | Pharmaceutical compositions and methods for treating cataracts | |
HUP0302130A3 (en) | Combination pharmaceutical compositions and process for their preparation | |
EP1351647A4 (en) | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | |
HUP0401042A3 (en) | Pharmaceutical compositions suitable for treating primary insomnia | |
IL153487A0 (en) | Pharmaceutical compositions and methods for use | |
HUP0203152A3 (en) | Method and compositions for treating pulmonary diseases | |
IL153897A0 (en) | Pharmaceutical compositions and methods for use | |
EP1089731A4 (en) | COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS | |
AU6137801A (en) | Method and composition for the treatment of angiogenesis | |
EP1253930A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER | |
AU2002337713A1 (en) | Pharmaceutical compositions and methods for treating cancer | |
AU2003257051A8 (en) | Composition and method for lowering cholesterol | |
EP1089732A4 (en) | COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS | |
AU5169200A (en) | Methods and compositions for treating breakthrough pain | |
ZA200100675B (en) | Compositions and methods for treating osteoporosis and lowering cholesterol. | |
AU2002342188A8 (en) | Methods and compositions for treating flavivirus-mediated disease | |
HU9902296D0 (en) | Pharmaceutical composition for treating caltification | |
AU2001253233A1 (en) | Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia | |
HUP0303141A3 (en) | Pharmaceutical compositions and process for their preparation | |
AU2002353915A1 (en) | Methods and compositions for treating rotavirus-mediated disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |